Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

353.83 +5.40 (+1.55%)
Streaming Delayed Price Updated: 2:58 PM EDT, Mar 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
News headline image
Amgen Crushes Third-Quarter Expectations On The Back Of Two Blockbusters ↗
The biotech giant also raised its sales and adjusted earnings outlook for the year. 
Via Investor's Business Daily
Topics Earnings
News headline image
Palantir Weighs On Wall Street, Bitcoin Slumps 5%: What's Moving Markets Tuesday? ↗
Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, offering a convenient excuse to take profits after strong year-to-date... 
Via Benzinga
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Price Over Earnings Overview: Amgen ↗
 
Via Benzinga
News headline image
Amgen Earnings: What To Look For From AMGN
Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings this Tuesday after market close. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
News headline image
You Won't Believe What Elon Musk Just Said About Quantum Computing (Spoiler Alert: It's Good News) ↗
Elon Musk had some encouraging thoughts following Alphabet's latest quantum breakthrough. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout
Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant... 
Via MarketMinute
Topics Intellectual Property
News headline image
AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs
San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of... 
Via TokenRing AI
Topics Artificial Intelligence Supply Chain
News headline image
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
News headline image
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks ↗
Via MarketBeat
News headline image
Marjorie Taylor Greene Buys Netflix Stock After Downbeat Q3 Earnings, Expands Big Tech Bet ↗
MTG "buys the dip" on Netflix (NFLX) stock after a bad Q3 report. See all 14 of her new purchases, including MSFT and AMZN. 
Via Benzinga
News headline image
Marjorie Taylor Greene Buys 6 Stocks: Buffett, Health Care — And This Magnificent 7 Stock ↗
Marjorie Taylor Greene discloses buying more stocks in October. Here's a look at what she added to her portfolio. 
Via Benzinga
News headline image
S&P 500 Healthcare Sector Navigates Mixed Market Waters on October 29, 2025
On October 29, 2025, the broader market exhibited a decidedly mixed performance, reflecting a prevailing sense of uncertainty among investors. Against this backdrop of fluctuating sentiment, the S&P... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
What Does the Market Think About Amgen Inc? ↗
 
Via Benzinga
News headline image
2 Value Stocks on Our Watchlist and 1 Facing Headwinds
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen's Immunology Pipeline Has Long-Term Potential: Analyst ↗
Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across multiple immune diseases. 
Via Benzinga
News headline image
1 Top Dividend Growth Stock to Buy Right Now ↗
Its shares might not remain undervalued for that much longer. 
Via The Motley Fool
Topics Economy Government Intellectual Property
News headline image
Halper Sadeh LLC Encourages Amgen Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
News headline image
Market Minute: Dow Soars, Apple Hits Record High as 20-Day Government Shutdown Fuels Gold Rally
The U.S. financial markets opened the week with a robust performance on October 20, 2025, as the Dow Jones Industrial Average (DJIA) extended its gains, and tech giant Apple Inc. (NASDAQ: AAPL) reached... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
2 Reasons to Like AMGN and 1 to Stay Skeptical
Although Amgen (currently trading at $299.86 per share) has gained 9.6% over the last six months, it has trailed the S&P 500’s 29.3% return during that period. This might have investors contemplating... 
Via StockStory
Topics Stocks
News headline image
United Therapeutics Forges Ahead with Share Repurchases, Not Dividends, Following July 2025 Volume Surge
In a financial landscape often fixated on consistent dividend payouts, United Therapeutics Corporation (NASDAQ: UTHR) stands out with a distinct capital allocation strategy. Contrary to market... 
Via MarketMinute
Topics Retirement
News headline image
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs? ↗
Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential impact on Eli Lilly and Pfizer. 
Via Benzinga
Topics Government
News headline image
Marjorie Taylor Greene, Cathie Wood Snap Up The Same 13 Stocks — Here's the Unlikely Portfolio Crossover ↗
A look at the stock owned by both Ark Funds and Congresswoman Marjorie Taylor Greene. 
Via Benzinga
News headline image
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity ↗
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline. 
Via Benzinga
News headline image
Dow Jones Stumbles with Fractional Dip, Signaling Cautious Market Sentiment Amidst Global Headwinds
New York, NY – October 15, 2025 – The Dow Jones Industrial Average (DJIA) experienced a fractional dip today, reflecting a palpable sense of caution pervading market sentiment. While other major... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Reflecting On Therapeutics Stocks’ Q2 Earnings: Amgen (NASDAQ:AMGN)
Looking back on therapeutics stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Amgen (NASDAQ:AMGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Trump Plans AstraZeneca Deal To Cut Drug Prices For Low-Income Americans ↗
Trump to announce new deal with AstraZeneca to lower prescription drug costs for Americans using most-favored-nation pricing model. 
Via Benzinga
Topics Government
News headline image
Trump Administration Engages Pharmacies, GoodRx For TrumpRx Launch ↗
Pharmacies and GoodRx are in talks to join TrumpRx, a new drug pricing site aiming to lower prescription costs for U.S. consumers. 
Via Benzinga
Topics Government
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
2 S&P 500 Stocks to Target This Week and 1 Facing Challenges
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.